MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis

A number of single nucleotide polymorphisms have been associated with disease predisposition in chronic lympho- cytic leukemia. A single nucleotide polymorphism in the MDM2 promotor region, MDM2SNP309, was shown to soothe the p53 pathway. In the current study, we aimed to clarify the effect of the M...

Full description

Bibliographic Details
Main Authors: Benner, Axel, Mansouri, Larry, Rossi, Davide, Majid, Aneela, Willander, Kerstin, Parker, Anton, Bond, Gareth, Pavlova, Sarka, Nückel, Holger, Merkel, Olaf, Ghia, Paolo, Montserrat, Emili, Kaderi, Mohd Arifin, Rosenquist, Richard, Gaidano, Gianluca, Dye, Martin J.S., Söderkvist, Peter, Linderholm, Mats, Oscier, David, Tvaruzkova, Zuzana, Pospisilova, Sarka, Dührse, Ulrich, Greil, Richard, Döhner, Hartmut, Stilgenbauer, Stephan, Zenz, Thorsten
Format: Article
Language:English
English
English
Published: Ferrata Storti Foundation 2014
Subjects:
Online Access:http://irep.iium.edu.my/38695/
http://irep.iium.edu.my/38695/1/MDM_Arifin_2014_Haematologica.pdf
http://irep.iium.edu.my/38695/4/38695_MDM2%20promotor%20polymorphism%20and%20disease%20characteristics%20in%20chronic%20lymphocytic%20leukemia_SCOPUS.pdf
http://irep.iium.edu.my/38695/5/38695_MDM2%20promotor%20polymorphism%20and%20disease%20characteristics%20in%20chronic%20lymphocytic%20leukemia_WoS.pdf
_version_ 1848781654705831936
author Benner, Axel
Mansouri, Larry
Rossi, Davide
Majid, Aneela
Willander, Kerstin
Parker, Anton
Bond, Gareth
Pavlova, Sarka
Nückel, Holger
Merkel, Olaf
Ghia, Paolo
Montserrat, Emili
Kaderi, Mohd Arifin
Rosenquist, Richard
Gaidano, Gianluca
Dye, Martin J.S.
Söderkvist, Peter
Linderholm, Mats
Oscier, David
Tvaruzkova, Zuzana
Pospisilova, Sarka
Dührse, Ulrich
Greil, Richard
Döhner, Hartmut
Stilgenbauer, Stephan
Zenz, Thorsten
author_facet Benner, Axel
Mansouri, Larry
Rossi, Davide
Majid, Aneela
Willander, Kerstin
Parker, Anton
Bond, Gareth
Pavlova, Sarka
Nückel, Holger
Merkel, Olaf
Ghia, Paolo
Montserrat, Emili
Kaderi, Mohd Arifin
Rosenquist, Richard
Gaidano, Gianluca
Dye, Martin J.S.
Söderkvist, Peter
Linderholm, Mats
Oscier, David
Tvaruzkova, Zuzana
Pospisilova, Sarka
Dührse, Ulrich
Greil, Richard
Döhner, Hartmut
Stilgenbauer, Stephan
Zenz, Thorsten
author_sort Benner, Axel
building IIUM Repository
collection Online Access
description A number of single nucleotide polymorphisms have been associated with disease predisposition in chronic lympho- cytic leukemia. A single nucleotide polymorphism in the MDM2 promotor region, MDM2SNP309, was shown to soothe the p53 pathway. In the current study, we aimed to clarify the effect of the MDM2SNP309 on chronic lym- phocytic leukemia characteristics and outcome. We performed a meta-analysis of data from 2598 individual patients from 10 different cohorts. Patients' data and genetic analysis for MDM2SNP309 genotype, immunoglobulin heavy chain variable region mutation status and fluorescence in situ hybridization results were collected. There were no dif- ferences in overall survival based on the polymorphism (log rank test, stratified by study cohort; P=0.76; GG geno- type: cohort-adjusted median overall survival of 151 months; TG: 153 months; TT: 149 months). In a multivariable Cox proportional hazards regression analysis, advanced age, male sex and unmutated immunoglobulin heavy chain variable region genes were associated with inferior survival, but not the MDM2 genotype. The MDM2SNP309 is unlikely to influence disease characteristics and prognosis in chronic lymphocytic leukemia. Studies investigating the impact of individual single nucleotide polymorphisms on prognosis are often controversial. This may be due to selec- tion bias and small sample size. A meta-analysis based on individual patient data provides a reasonable strategy for prognostic factor analyses in the case of small individual studies. Individual patient data-based meta-analysis can, therefore, be a powerful tool to assess genetic risk factors in the absence of large studies.
first_indexed 2025-11-14T15:53:00Z
format Article
id iium-38695
institution International Islamic University Malaysia
institution_category Local University
language English
English
English
last_indexed 2025-11-14T15:53:00Z
publishDate 2014
publisher Ferrata Storti Foundation
recordtype eprints
repository_type Digital Repository
spelling iium-386952020-10-28T01:38:30Z http://irep.iium.edu.my/38695/ MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis Benner, Axel Mansouri, Larry Rossi, Davide Majid, Aneela Willander, Kerstin Parker, Anton Bond, Gareth Pavlova, Sarka Nückel, Holger Merkel, Olaf Ghia, Paolo Montserrat, Emili Kaderi, Mohd Arifin Rosenquist, Richard Gaidano, Gianluca Dye, Martin J.S. Söderkvist, Peter Linderholm, Mats Oscier, David Tvaruzkova, Zuzana Pospisilova, Sarka Dührse, Ulrich Greil, Richard Döhner, Hartmut Stilgenbauer, Stephan Zenz, Thorsten Q Science (General) RC254 Neoplasms. Tumors. Oncology (including Cancer) A number of single nucleotide polymorphisms have been associated with disease predisposition in chronic lympho- cytic leukemia. A single nucleotide polymorphism in the MDM2 promotor region, MDM2SNP309, was shown to soothe the p53 pathway. In the current study, we aimed to clarify the effect of the MDM2SNP309 on chronic lym- phocytic leukemia characteristics and outcome. We performed a meta-analysis of data from 2598 individual patients from 10 different cohorts. Patients' data and genetic analysis for MDM2SNP309 genotype, immunoglobulin heavy chain variable region mutation status and fluorescence in situ hybridization results were collected. There were no dif- ferences in overall survival based on the polymorphism (log rank test, stratified by study cohort; P=0.76; GG geno- type: cohort-adjusted median overall survival of 151 months; TG: 153 months; TT: 149 months). In a multivariable Cox proportional hazards regression analysis, advanced age, male sex and unmutated immunoglobulin heavy chain variable region genes were associated with inferior survival, but not the MDM2 genotype. The MDM2SNP309 is unlikely to influence disease characteristics and prognosis in chronic lymphocytic leukemia. Studies investigating the impact of individual single nucleotide polymorphisms on prognosis are often controversial. This may be due to selec- tion bias and small sample size. A meta-analysis based on individual patient data provides a reasonable strategy for prognostic factor analyses in the case of small individual studies. Individual patient data-based meta-analysis can, therefore, be a powerful tool to assess genetic risk factors in the absence of large studies. Ferrata Storti Foundation 2014-08-01 Article PeerReviewed application/pdf en http://irep.iium.edu.my/38695/1/MDM_Arifin_2014_Haematologica.pdf application/pdf en http://irep.iium.edu.my/38695/4/38695_MDM2%20promotor%20polymorphism%20and%20disease%20characteristics%20in%20chronic%20lymphocytic%20leukemia_SCOPUS.pdf application/pdf en http://irep.iium.edu.my/38695/5/38695_MDM2%20promotor%20polymorphism%20and%20disease%20characteristics%20in%20chronic%20lymphocytic%20leukemia_WoS.pdf Benner, Axel and Mansouri, Larry and Rossi, Davide and Majid, Aneela and Willander, Kerstin and Parker, Anton and Bond, Gareth and Pavlova, Sarka and Nückel, Holger and Merkel, Olaf and Ghia, Paolo and Montserrat, Emili and Kaderi, Mohd Arifin and Rosenquist, Richard and Gaidano, Gianluca and Dye, Martin J.S. and Söderkvist, Peter and Linderholm, Mats and Oscier, David and Tvaruzkova, Zuzana and Pospisilova, Sarka and Dührse, Ulrich and Greil, Richard and Döhner, Hartmut and Stilgenbauer, Stephan and Zenz, Thorsten (2014) MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. Haematologica, 99 (8). pp. 1285-1291. ISSN 1592-8721 https://pubmed.ncbi.nlm.nih.gov/25082786/ 10.3324/haematol.2013.101170
spellingShingle Q Science (General)
RC254 Neoplasms. Tumors. Oncology (including Cancer)
Benner, Axel
Mansouri, Larry
Rossi, Davide
Majid, Aneela
Willander, Kerstin
Parker, Anton
Bond, Gareth
Pavlova, Sarka
Nückel, Holger
Merkel, Olaf
Ghia, Paolo
Montserrat, Emili
Kaderi, Mohd Arifin
Rosenquist, Richard
Gaidano, Gianluca
Dye, Martin J.S.
Söderkvist, Peter
Linderholm, Mats
Oscier, David
Tvaruzkova, Zuzana
Pospisilova, Sarka
Dührse, Ulrich
Greil, Richard
Döhner, Hartmut
Stilgenbauer, Stephan
Zenz, Thorsten
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis
title MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis
title_full MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis
title_fullStr MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis
title_full_unstemmed MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis
title_short MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis
title_sort mdm2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis
topic Q Science (General)
RC254 Neoplasms. Tumors. Oncology (including Cancer)
url http://irep.iium.edu.my/38695/
http://irep.iium.edu.my/38695/
http://irep.iium.edu.my/38695/
http://irep.iium.edu.my/38695/1/MDM_Arifin_2014_Haematologica.pdf
http://irep.iium.edu.my/38695/4/38695_MDM2%20promotor%20polymorphism%20and%20disease%20characteristics%20in%20chronic%20lymphocytic%20leukemia_SCOPUS.pdf
http://irep.iium.edu.my/38695/5/38695_MDM2%20promotor%20polymorphism%20and%20disease%20characteristics%20in%20chronic%20lymphocytic%20leukemia_WoS.pdf